Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care.

Wade AJ, Doyle JS, Draper B, Howell J, Iser D, Roberts SK, Kemp W, Thompson AJ, Hellard ME

(2021), J VIRAL HEPATITIS, 28(1), 217-8

DOI: 10.1111/jvh.13391

Improvements in transition times through the HIV cascade of care among gay and bisexual men with a new HIV diagnosis in New South Wales and Victoria, Australia (2012-19): a longitudinal cohort study.

van Santen DK, Asselin J, Haber NA, Traeger MW, Callander D, Donovan B, El-Hayek C, McMahon JH, Petoumenos K, McManus H, Hoy JF, Hellard M, Guy R, Stoové M; TAIPAN investigators.

(2021), Lancet HIV, 8(10), e623-e632

DOI: 10.1016/s2352-3018(21)00155-7

The introduction of a mandatory mask policy was associated with significantly reduced COVID-19 cases in a major metropolitan city.

Scott N, Saul A, Spelman T, Stoove M, Pedrana A, Saeri A, Grundy E, Smith L, Toole M, McIntyre CR, Crabb BS, Hellard M

(2021), PLoS One, 16(7), e0253510

DOI: 10.1371/journal.pone.0253510

The phases of hepatitis C elimination: achieving WHO elimination targets.

Pedrana A, Munari S, Stoové M, Doyle J, Hellard M

(2021), LANCET GASTROENTEROL, 6(1), 6-Aug

DOI: 10.1016/s2468-1253(20)30366-6

A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.

Palmer AY, Chan K, Gold J, Layton C, Elsum I, Hellard M, Stoove M, Doyle JS, Pedrana A, Scott N; EC Partnership

(2021), J VIRAL HEPATITIS, 28(11), 1624-34

DOI: 10.1111/jvh.13596

Barriers and facilitators to pre-exposure prophylaxis among African migrants in high income countries: a systematic review

Mwaturura C, Traeger M, Lemoh C, Stoove M, Price B, Coelho A, Mikola M, Ryan KE, Wright E

(2021), Sex Health, 18(2), 130-9

DOI: 10.1071/sh20175

A new method for estimating the incidence of infectious diseases.

McManus H, Callander D, Asselin J, McMahon J, Hoy JF, Templeton DJ, Fairley CK, Donovan B, Pedrana AE, Keen P, Wilson DP, Elliott J, Kaldor J, Liaw ST, Petoumenos K, Holt M, Hellard ME, Grulich AE, Carr A, Stoové MA, Guy RJ

(2021), Am J Epidemiol, 190(7), 1386–95

DOI: 10.1093/aje/kwab014

Implications of HIV self-testing for other sexually transmissible infection testing and broader sexual health needs: a mixed methods study of gay and bisexual men in Australia.

Leitinger D, Ryan K, Wilkinson AL, Pedrana A, Hellard M, Stoové M

(2021), Sex Transm Dis, 48(6), 417-23

DOI: 10.1097/olq.0000000000001324

Early outpatient treatment of SARS-CoV-2 (COVID-19): A comment.

Korman TM, McMahon JH

(2021), AM J MED, 134(3), e220-e221

DOI: 10.1016/j.amjmed.2020.08.044

Multicentre stepped-wedge cluster randomised controlled trial of an antimicrobial stewardship programme in residential aged care: protocol for the START trial.

Jokanovic N, Haines T, Cheng AC, Holt KE, Hilmer SN, Jeon YH, Stewardson AJ, Stuart RL, Spelman T, Peel TN, Peleg AY; START Trial Group

(2021), BMJ Open, 11(3), e046142

DOI: 10.1136/bmjopen-2020-046142

Affordable treatment and political commitment are crucial to eliminate hepatitis C globally.

Hellard M, Pedrana A, Draper B

(2021), LANCET GASTROENTEROL, 6(6), 414-6

DOI: 10.1016/s2468-1253(21)00135-7

Effect of Rosuvastatin therapy on biomarkers of inflammation and immune activation in people with Human Immunodeficiency Virus at intermediate cardiovascular risk.

Hearps AC, Angelovich TA, Trevillyan JM, Wong ME, Calmy A, Hoy JF, Jaworowski A

(2021), J Infect Dis, 224(4), 667-72

DOI: 10.1093/infdis/jiaa775

Letter to the Editor: Recommendations for implementing hepatitis C virus care in homeless shelters: The stakeholder perspective.

Harney B, McColl R, Pedrana A, Morrison E, Doyle J, Hellard M, Higgs P

(2021), Hepatol Commun, 5(1), 146-7

DOI: 10.1002/hep4.1616

Routine testing for syphilis and other bacterial sexually transmissible infections is required among people in prison.

Harney B, Doyle J, Hellard M, Stoové M, Winter R

(2021), Sex Transm Dis, 48(10), e153

DOI: 10.1097/olq.0000000000001532

Letter in response: Psychiatrists can treat hepatitis C.

Harney BL, Brereton R, Whitton B, Pietrzak D, Paige E, Roberts SK, Birks S, Saraf S, Hellard ME, Doyle JS

(2021), J VIRAL HEPATITIS, 28(12), 1765-6

DOI: 10.1111/jvh.13619

Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.

Goutzamanis S, Spelman T, Harney B, Dietze P, Stoové M, Higgs P, Thompson A, Doyle JS, Hellard M; Treatment, Prevention Study group.

(2021), J VIRAL HEPATITIS, 28(7), 1068--77

DOI: 10.1111/jvh.13516

Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study.

Goutzamanis S, Horyniak D, Doyle JS, Hellard M, Higgs P; Treatment and Prevention Study group.

(2021), Harm Reduct J, 18(1), 73

DOI: 10.1186/s12954-021-00516-1

Peer to peer communication about hepatitis C treatment amongst people who inject drugs: A longitudinal qualitative study.

Goutzamanis S, Doyle JS, Horyniak D, Higgs P, Hellard M; TAP study group

(2021), Int J Drug Policy, 87, 102983

DOI: 10.1016/j.drugpo.2020.102983

Outcomes of the CT2 Study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, Myanmar.

Draper B, Htay H, Pedrana A, Yee WL, Howell J, Kyi KP, Naing W, Aung KS, Markby J, Easterbrook P, Bowring A, Aung W, Sein YY, Nwe N, Myint KT, Shilton S, Hellard M

(2021), Liver Int, 41(11), 2578-89

DOI: 10.1111/liv.14983

Health service utilisation and experiences of stigma among people who inject drugs in Melbourne, Australia.

Djordjevic F, Ryan K, Gunn J, Brener L, O'Keefe D, Draper B, Schroeder S, Gold J, Treloar C, Broady T, Dietze P, Hellard M, Pedrana A

(2021), J VIRAL HEPATITIS, 28(12), 1738-43

DOI: 10.1111/jvh.13612

3 4 5 6 7